NCT06722664View on ClinicalTrials.gov

Efficacy and Safety of OsrhCT and Dimethicone Emulsion Before Upper Endoscopy on Visualization of the Gastric Mucosa.

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

336

Participants

Timeline

Start Date

December 19, 2024

Primary Completion Date

May 15, 2025

Study Completion Date

May 15, 2025

Conditions
Gastric Mucosal Lesion
Interventions
DRUG

Recombinant Human Chymotrypsin(OsrhCT) 4000U

Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 4,000U/vial, freeze-dried powder

DRUG

Placebo for Recombinant Human Chymotrypsin(OsrhCT)

Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 0 U/vial, freeze-dried powder

DRUG

Dimethicone emulsion 4ml

Dimethicone emulsion，produced by Sichuan Jian Neng Pharmaceutical Co., Ltd, 6ml/bottle.

Trial Locations (5)

Unknown

Beijing Friendship Hospital, Beijing

Chinese PLA Central Theatre General Hospital, Wuhan

Renmin Hospital of Wuhan University, Wuhan

the Central Hospital of Wuhan, Wuhan

Inner Mongolia Autonomous Region People's Hospital, Hohhot

Sponsors
All Listed Sponsors
collaborator

Beijing Friendship Hospital

OTHER

lead

Healthgen Biotechnology Corp.

INDUSTRY

NCT06722664 - Efficacy and Safety of OsrhCT and Dimethicone Emulsion Before Upper Endoscopy on Visualization of the Gastric Mucosa. | Biotech Hunter | Biotech Hunter